Nuclease News and Research

RSS

Sangamo BioSciences initiates two new clinical trials of ZFP Therapeutics

Sangamo BioSciences, Inc. announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study in diabetic neuropathy (DN) and a Phase 1 trial in glioblastoma, as well as the renewal of $3.0 million in funding for the Phase 2b trial by the Juvenile Diabetes Research Foundation International (JDRF).

11 Jan 2010

USPTO issues Notice of Allowance for U.S. patent application in the 'Crooke' patent family

Isis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application (No. 10/078,949) in the “Crooke” patent family, which broadly covers chemically modified RNA-containing therapeutics.

16 Dec 2009

Transgenomic's SURVEYOR Scan K-RAS mutation detection kit launched

Transgenomic, Inc. announced today the launch of its SURVEYOR Scan K-RAS kit, the first in a family of mutation detection kits the company plans to offer featuring its proprietary SURVEYOR Nuclease and WAVE® HS DHPLC platform. SURVEYOR Scan technology is a novel approach to mutation detection that uses a PCR amplification reaction and hybridization to form heteroduplex DNA molecules in samples with K-RAS mutation.

9 Dec 2009

Data from Phase 1 safety study of SB-728-T announced

Sangamo BioSciences, Inc. announced today that data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were inadvertently and prematurely disclosed on the internet.

19 Nov 2009

Sangamo BioSciences awarded a grant to develop zinc finger nuclease-based stem cell therapy for AIDS

Sangamo BioSciences, Inc. announced today that the California Institute for Regenerative Medicine (CIRM) has granted a $14.5 million Disease Team Research Award to develop an AIDS-related lymphoma therapy based on the application of its zinc finger nuclease (ZFN) gene-editing technology in stem cells.

29 Oct 2009

Roche NimbleGen and High Throughput Genomics enter into a supply agreement

Roche NimbleGen and High Throughput Genomics, Inc. (HTG), provider of the quantitative Nuclease Protection Assay (qNPA), have entered into a supply agreement. Under the agreement, Roche NimbleGen will provide HTG with high density, multiplex DNA microarray slides for advanced gene expression analysis.

21 Oct 2009

Sigma-Aldrich launches SAGEspeed, a program for developing human disease models in rodents

Sigma-Aldrich® (Nasdaq: SIAL) today announced the launch of SAGEspeed(TM), a program to develop human disease models in rodents using its proprietary novel CompoZr(TM) Zinc Finger Nuclease (ZFN) gene editing technology (http://www.compozrzfn.com).

19 Oct 2009

Transgenomic adds DFCI's Cold-PCR mutation detection technology to its portfolio

Transgenomic, Inc. (OTC Bulletin Board: TBIO). The company announced today that it has licensed a high-sensitivity mutation detection technology called Cold-PCR from the Dana-Farber Cancer Institute (DFCI), Boston, MA.

9 Oct 2009

Sigma-Aldrich and Sangamo Biosciences extend license agreement for ZFP technology

Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals.

5 Oct 2009

U.S. PTO to reexamine the patents in Cellectis-Precision BioSciences litigation

Precision BioSciences, Inc. today announced that the United States Patent and Trademark Office (PTO) has granted Precision’s requests for inter partes reexamination of U.S. Patent Nos. 6,610,545 (the ‘545 patent) and 7,309,605 (the ‘605 patent), which Cellectis SA (Alternext: ALCLS) has asserted against Precision in litigation.

29 Sep 2009

FDA accepts Sangamo's IND for repeat-dosing in Phase 1 clinical trial of SB-728-T ZFN-based therapeutic

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania.

23 Sep 2009

Sigma-Aldrich scientists to leverage proprietary gene editing technology to develop genetically-engineered rodent research models

Sigma-Aldrich(R) (Nasdaq: SIAL) announced today that scientists at its new Sigma Advanced Genetic Engineering (SAGE(TM)) Labs in St. Louis will leverage its exclusive CompoZr(TM) Zinc Finger Nuclease (ZFN) gene editing technology (www.compozrzfn.com) to define, develop and offer a new generation of genetically-engineered rodent research models. Such models are commonly used to study disease states in humans and play a key role in the drug discovery process.

24 Aug 2009

A new technique for modifying plant genes

Researchers at the University of Minnesota and Massachusetts General Hospital have used a genome engineering tool they developed to make a model crop plant herbicide-resistant without significant changes to its DNA.

30 Apr 2009

Sangamo BioSciences starts trial of CCR5-ZFP therapeutic to treat HIV/AIDS

Sangamo BioSciences, Inc. has announced that its collaborators at the University of Pennsylvania have opened a Phase 1 clinical trial to evaluate SB-728-T for the treatment of HIV/AIDS.

5 Feb 2009

Virtuoso cell engineering

University of Michigan researchers have discovered that a key protein in cells plays a critical role in not one, but two processes affecting the development of cancer.

6 Jan 2009

Gene technique that alters CCR5-producing gene increases resistance to HIV in mice

Altering the gene that produces CCR5 protein on the surface of immune cells using a harmless virus was found to significantly increase resistance to HIV in mice, according to a study published Sunday in the journal Nature Biotechnology, the Press Trust of India reports (Press Trust of India, 7/1).

4 Jul 2008

More efficient gene targeting improves prospects for gene therapy

The Nobel prize-winning MRC scientist Sir Aaron Klug and a team from an American company, Sangamo BioSciences, have announced a new way to target genes that may revolutionise medical research and pave the way for new treatments.

20 Mar 2008

A nanoplasmonic molecular ruler for measuring nuclease activity and DNA footprinting

The interactions between proteins and nucleic acids play a critical role in some of life’s most crucial biochemical processes, including gene expression and protein production, and some promising anticancer agents exert their effects by interfering with these interactions.

16 Oct 2006

WRN exonuclease structure and molecular mechanism imply an editing role in DNA end processing

A team of scientists from Lawrence Berkeley National Laboratory and the Scripps Research Institute has determined the crystal structure and molecular mechanisms of a key part of WRN, a protein that protects humans from premature aging and cancer.

23 Apr 2006

Protein called CPSF73 performs a necessary step in the production of human chromosomes

The study found that a protein called CPSF73 acts like scissors to cut strands of histone messenger RNA (mRNA) in the cell nucleus. This cutting action produces the mRNA needed to create histone proteins that combine with DNA to form chromosomes.

12 Oct 2005